New Document
Corporate Profile Products Investor Relations News Room Careers Contact Us Manufacturing Quality Assurance Environment, Health & Safety R & D Contract Research & Manufacturing Home
 


Financial Year 2007 - 2008

Quarter IV
(March 2008)

Quarter III
(December 2007)

Quarter II
(September 2007)

Quarter I
(June 2007)

Financial Year 2006 - 2007

Quarter IV
(March 2007)

Quarter III
(December 2006)

Quarter II
(September 2006)

Quarter I
(June 2006)

Financial Year 2005 - 2006

Quarter IV
(March 2006)

Quarter III
(December 2005)

Quarter II
(September 2005)

Quarter I
(June 2005)

Financial Year 2004 - 2005

Quarter IV
(March 2005)

Quarter III
(December 2004)

Quarter II
(September 2004)

Quarter I
(June 2004)

Financial Year 2003 - 2004

Quarter IV
(March 2004)

Quarter III
(December 2003)

Quarter II
(September 2003)

Quarter I
(June 2003)

Financial Year 2002 - 2003

Quarter IV
(March 2003)

Quarter III
(December 2002)

Quarter II
(September 2002)

Quarter I
(June 2002)


MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31st MARCH 2008

(Rs.in Million )
Sl. No Particulars First Quarter ended 30th June Accounting
Year ended
31st March 2002
(Audited)
2002 (Audited) 2001 (UnAudited)
  Gross Sales 506.87 352.09 1038.89
01.
02.
03.




04.
05.
06.

07.
08.

09.
10.
11.

12.

13.
14.

15.
Net Sales
Other Income
Total Expenditure
a) (Increase) / Decrease in Stock
b) Consumption of Raw materials
c) Other Expenditure
d) Staff Cost
Interest
Depreciation
Profit before Tax & Extraordinary
items (1+2-3-4-5)
Provision for Tax
Net Profit after Tax and before
Extraordinary items (6-7)
Provision for Deferred Tax
Income Tax relating to earlier years
Provision for deferred tax for earlier
years
Net Profit after Tax and Extraordinary
items (8-9-10-11)
Paid up Equity Share Capital
Reserves excluding revaluation
reserves
Basic & Diluted E.P.S in Rs.
     (Not Annualised for the quarter)
489.53
0.76

24.91
144.02
85.05
13.17
8.56
4.97

209.58
3.00

206.58
3.63
--

--

202.94
71.87

--
28.23
311.84
--

(10.34)
221.62
64.43
9.88
3.47
2.44

20.33
--

20.33
--
--

--

20.33
71.93

--
4.46
932.07
1.78

(74.37)
670.52
180.75
49.45
16.73
15.25

75.51
4.60

70.91
15.70
1.36

9.02

44.82
71.93

143.25
10.83
Notes :

  1. The above Audited Financial Results were taken on record by the Board of Directors in their meeting held on 25th July,02
  2. Income tax is computed for the quarter on the basis of annualized taxable income for the Asst.Year 2003-04 after considering various deductions. Provision for Deffered Tax is computed for the quarter.
  3. Accounting Standard No.17 dealing with Segment Accounting is not applicable as the company is engaged only in the segment of manufacture and sale of bulk drugs.
  4. The Company has completed the acquisition of 100% Equity consisting of 10,90,000 Equity shares of Rs.10/- each in Medikon Laboratories Ltd at a cost of Rs.143.38 lakhs.
  5. The Company has entered into agreements to acquire 51.42% out of the total equity capital of Rs.1924.45 lakhs in Medicorp Technologies India Ltd at an aggregate cost of Rs.2272 lakhs. Consequently the company has made public offer as per SEBI Regulations which opened on 9th July,2002.

  For and on behalf of the Board



Place : Secunderabad
Date : 25th July 2002
Sd/-
N.PRASAD
Chairman & Managing Director


Foote Page